Company Filing History:
1 out of 1,291 
1 out of 24 
Years Active: 2018
Title: The Innovative Contributions of Phillip Krapf
Introduction
Phillip Krapf is a notable inventor based in Much, Germany. He has made significant contributions to the field of radiochemistry, particularly in the development of methods for producing radiolabeled compounds. His work has implications for medical imaging, especially in the diagnosis of prostate cancer.
Latest Patents
Krapf holds a patent titled "Method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer." This patent describes novel, efficient, time-saving, and reliable radiofluorination procedures for producing fluorine-18 labeled active esters. The methods involve nucleophilic substitution of the corresponding onium precursors with fluorine-18. The active esters produced, including [F]F-Py-TFP and [F]TFB, are utilized to prepare PSMA-specific PET tracers such as [F]DCFPyL. The key advantages of these methods are their efficiency, short preparation time, and excellent suitability for automation. A pharmaceutical composition containing at least one PSMA-specific PET tracer prepared by this method is particularly useful for positron emission tomography (PET) imaging, especially in imaging prostate tumors.
Career Highlights
Throughout his career, Krapf has worked with prestigious institutions, including the Max Planck Society for the Advancement of Science and the University of Cologne. His research has focused on enhancing the efficiency of radiolabeling techniques, which are crucial for the development of diagnostic imaging agents.
Collaborations
Krapf has collaborated with notable colleagues such as Bernd Neumaier and Boris Zlatopolskiy. Their combined expertise has contributed to advancements in the field of radiochemistry and medical imaging.
Conclusion
Phillip Krapf's innovative work in the production of radiolabeled compounds has made a significant impact on medical imaging, particularly in the diagnosis of prostate cancer. His contributions continue to influence the field and enhance the capabilities of positron emission tomography.